These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11398913)

  • 1. Telithromycin.
    Balfour JA; Figgitt DP
    Drugs; 2001; 61(6):815-29; discussion 830-1. PubMed ID: 11398913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telithromycin.
    Wellington K; Noble S
    Drugs; 2004; 64(15):1683-94; discussion 1695-6. PubMed ID: 15257629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM; Dever LL
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study.
    Quinn J; Ruoff GE; Ziter PS
    Clin Ther; 2003 Feb; 25(2):422-43. PubMed ID: 12749505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
    Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
    Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis.
    Zervos MJ; Heyder AM; Leroy B
    J Int Med Res; 2003; 31(3):157-69. PubMed ID: 12870368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telithromycin: the first ketolide antimicrobial.
    Nguyen M; Chung EP
    Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ketolides: a critical review.
    Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
    Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
    Norrby SR; Quinn J; Rangaraju M; Leroy B
    Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
    Mathers Dunbar L; Hassman J; Tellier G
    Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telithromycin: an oral ketolide for respiratory infections.
    Bearden DT; Neuhauser MM; Garey KW
    Pharmacotherapy; 2001 Oct; 21(10):1204-22. PubMed ID: 11601667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
    Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
    Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis.
    Roos K; Tellier G; Baz M; Leroy B; Rangaraju M
    J Infect; 2005 Apr; 50(3):210-20. PubMed ID: 15780415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis.
    Luterman M; Tellier G; Lasko B; Leroy B
    Ear Nose Throat J; 2003 Aug; 82(8):576-80, 82-4, 586 passim. PubMed ID: 14503094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections.
    Darkes MJ; Perry CM
    Am J Respir Med; 2003; 2(2):175-201. PubMed ID: 14720016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis.
    Buchanan PP; Stephens TA; Leroy B
    Am J Rhinol; 2003; 17(6):369-77. PubMed ID: 14750614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.